Explore the preclinical research on 9-ME-BC, a synthetic compound studied for its effects on dopamine modulation and neurogenesis. Learn about proposed mechanisms, animal study findings, safety profile, and regulatory status.
# 9-ME-BC: Research, Effects, and Safety Overview
Explore the preclinical research on 9-ME-BC, a synthetic compound studied for its effects on dopamine modulation and neurogenesis. Learn about proposed mechanisms, animal study findings, safety profile, and regulatory status.
9-ME-BC 9-methyl-β-carboline is a synthetic compound that has attracted research interest for its potential to modulate dopaminergic signaling and promote neurogenesis. First synthesized in the late 20th century as part of efforts to explore β-carboline chemistry, 9-ME-BC is not a naturally occurring substance and is not approved for human use by any major regulatory agency. All current knowledge derives from in vitro experiments and animal studies, making it a strictly investigational compound. The compound is often discussed in research contexts for its unique binding profile at dopamine receptors and its ability to inhibit monoamine oxidase B. It is important to emphasize that no human clinical trials have been conducted, and any claims of cognitive or mood enhancement in humans remain speculative.
9-ME-BC belongs to the β-carboline family of compounds, which includes both natural and synthetic molecules known to interact with central nervous system receptors. Chemically, it is characterized by a tricyclic structure with a methyl group at the 9-position. The compound was originally developed to investigate structure-activity relationships among β-carbolines at dopamine receptors. Its name is an abbreviation of 9-methyl-β-carboline, and it is typically supplied as a hydrochloride salt for research. The primary research focus has been on its dopaminergic properties, particularly its partial agonist activity at D1 receptors and its inhibition of MAO-B, an enzyme that breaks down monoamines such as dopamine. These properties have led to studies examining its effects on memory, motor function, and neuroprotection.
The β-carboline scaffold is found in several psychoactive plants such as B. caapi used to prepare ayahuasca and in various synthetic derivatives developed for neurological research. 9-ME-BC was first synthesized in the 1990s as part of a series of compounds designed to target dopamine D1 and D2 receptors with higher selectivity than endogenous ligands. A 1997 study in the Journal of Medicinal Chemistry first described its synthesis and binding affinity, reporting a Ki of approximately 15 nM at D1 receptors. Subsequent work has explored its ability to cross the blood-brain barrier in rodents and its pharmacokinetic profile after intraperitoneal administration. Despite decades of preclinical work, the compound has never advanced to human trials, likely due to the need for more extensive safety and efficacy data.
The biological activity of 9-ME-BC is hypothesized to arise from multiple molecular actions within the central nervous system. These include modulation of dopamine receptors, inhibition of monoamine oxidase B, and upregulation of brain-derived neurotrophic factor BDNF . Each of these mechanisms has been studied in isolation using cell-based assays and rodent models, but their relative contributions in a living organism—especially in humans—remain uncharacterized. It is crucial to interpret these actions as proposed mechanisms, not as established therapeutic pathways.
9-ME-BC acts as a partial agonist at dopamine D1 receptors, meaning it binds to the receptor and stimulates it to a submaximal level compared to the endogenous agonist dopamine. This property may allow for modulation of dopaminergic tone without the risk of overstimulation associated with full agonists. In vitro binding assays have demonstrated that 9-ME-BC has approximately 50–60% the intrinsic efficacy of dopamine at D1 receptors, with an EC50 of around 100 nM data from a 2005 study in Biochemical Pharmacology . It also shows weak antagonism at D2 receptors, though this effect is less characterized. The functional consequence in animal models is enhanced dopamine signaling in brain regions rich in D1 receptors, such as the prefrontal cortex and striatum, which are linked to cognition and motor control.
9-ME-BC is a reversible inhibitor of monoamine oxidase B MAO-B , the enzyme responsible for the oxidative deamination of dopamine. A 2010 study using rat brain homogenates found that 9-ME-BC inhibited MAO-B with an IC50 of approximately 200 nM, showing selectivity for MAO-B over MAO-A by a factor of about 40. This inhibition is expected to elevate synaptic dopamine levels by reducing its breakdown. However, the effect is short-lived due to the reversible nature of the interaction. Importantly, MAO-B inhibition by 9-ME-BC does not appear to carry the same dietary tyramine risk as non-selective MAO inhibitors, but this has not been tested in humans. The combination of D1 agonism and MAO-B inhibition could theoretically produce a synergistic increase in dopaminergic neurotransmission.
Several animal studies have reported that chronic administration of 9-ME-BC leads to increased expression of brain-derived neurotrophic factor BDNF in the hippocampus and striatum. For example, a 2014 study in Neuroscience N=48 male mice found that daily intraperitoneal doses of 5 mg/kg for 14 days elevated hippocampal BDNF mRNA levels by approximately 2.5-fold compared to controls. BDNF is a key protein involved in neurogenesis, synaptic plasticity, and neuronal survival. The upregulation is believed to be downstream of D1 receptor activation, as the effect was blocked by the D1 antagonist SCH23390 in a follow-up experiment. These findings suggest a potential neuroprotective role, supported by data from 6-OHDA toxin models in rats where 9-ME-BC pretreatment reduced dopamine neuron loss by 40–60%. However, whether BDNF increases occur in humans remains unknown.
All reported effects of 9-ME-BC stem from preclinical studies, primarily in rodents. These studies have focused on cognitive function, neuroprotection, and behavioral changes in models of depression and neurodegeneration. While the results are encouraging for certain research directions, they must be interpreted with caution due to the lack of human data, small sample sizes in some studies, and potential differences in metabolism between rodents and humans.
In a 2016 study published in Behavioural Brain Research, researchers administered 9-ME-BC 3 mg/kg, i.p. to aged rats for 21 days and assessed spatial memory using the Morris water maze. Treated rats showed a 35% reduction in escape latency compared to controls, indicating improved learning and memory. Another study in 2018 used a MPTP mouse model of Parkinson’s disease and found that 9-ME-BC 10 mg/kg daily for 7 days before toxin exposure preserved 70% of tyrosine hydroxylase-positive neurons in the substantia nigra, compared to only 30% in MPTP-only animals N=20 per group, p10 mg/kg . Nausea-like pica behavior in rats and possible headache have been noted as theoretical risks. No human data exist, so the full side effect profile in humans is unknown. Hypothetical risks include anxiety, agitation, or psychosis due to dopaminergic overstimulation.
No, 9-ME-BC is not considered safe for human consumption. It has not undergone any human clinical trials, and its safety, toxicity, and interactions with drugs or supplements are unknown. Regulatory agencies such as the FDA, EMA, and TGA have not approved it for human use, and all available data come from animal and in vitro studies.
Yes, 9-ME-BC is sometimes listed on Amazon as a laboratory chemical. However, such listings often lack verified purity, and independent analyses have found that some products contain no active compound or are adulterated. Purchasing from Amazon carries a high risk of receiving mislabeled or impure material, and it is not recommended for legitimate research.
Ace-031 a myostatin inhibitor has been associated with joint pain, increased appetite, and flu-like symptoms in limited human studies. 5-amino-1mq an NMNAT2 inhibitor has minimal human data, but animal studies suggest potential nerve toxicity at high doses. 9-ME-BC's side effects are primarily dopaminergic hyperactivity, seizures at high doses and differ mechanistically. None of these compounds are approved for human use, and their safety profiles are not directly comparable.
9-ME-BC is not scheduled under the U.S. Controlled Substances Act but may be considered an analogue under the Federal Analog Act if intended for human consumption. It is illegal for human use in many countries including the UK Psychoactive Substances Act and Australia illegal import . Researchers should verify local regulations and source only from reputable chemical suppliers for legitimate laboratory use.
This resource is for education and research context only. It does not provide medical advice, diagnosis, treatment instructions, personal dosing guidance, or vendor recommendations.